NASDAQ OMX

Percona Announces New Cloud and Container Partners

Dela

Partnerships with Microsoft and Mesosphere Make it Easier to Ensure Optimal Performance

RALEIGH, N.C., April 26, 2018 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MariaDB®, MongoDB®, PostgreSQL, and other open source database solutions and services, announced new partnerships to make it easier for organizations to take advantage of cloud and container environments to run their open source databases, ensuring optimal performance while shifting their focus to improving applications and better supporting the business.

With open source databases now standard in the enterprise, organizations are increasingly looking to deploy those databases in public cloud environments to benefit from the flexibility, scalability and economics of the cloud. Today's announcements, including a new partnership with Microsoft to support Microsoft Azure customers, along with the availability of Percona Server for MongoDB in the Mesosphere DC/OS community, reflect Percona's commitment to providing comprehensive support for open source databases in cloud deployments. Percona previously announced support partnerships with Google to offer Google Cloud SQL services and Amazon Web Services to support the use of Amazon Elastic Compute Cloud (Amazon EC2), Amazon Relational Database Service (Amazon RDS), and Amazon Aurora on AWS.

Partnership with Microsoft for Microsoft Azure Customers
Percona has entered into a partnership with Microsoft, a Platinum Sponsor of the Percona Live Open Source Database Conference, to make it easier for clients to take advantage of the Microsoft Azure cloud platform. Percona software will now be available via the Azure Marketplace, simplifying deployment into Azure Virtual Machines. Additionally, the Percona DBA Service for Microsoft Azure, as well as other support services, will help Azure customers derive the most benefit from their open source database environments.

Percona Server for MongoDB Certified on Mesosphere
Percona has partnered with Mesosphere to deliver Percona Server for MongoDB on Mesosphere DC/OS. As reliance on hybrid, on-premises, and cloud environments continues to grow, enterprises are increasingly turning to Mesosphere to run large-scale applications. DC/OS is a single, integrated and easy-to-use platform for cutting edge technology tools like containers, microservices, machine learning and more that abstracts away the complexity of distributed computing. Percona Server for MongoDB offers these organizations the best of both worlds: a free and open source, enterprise-grade version of MongoDB backed by the renowned experts at Percona, plus the confidence that the solution meets the rigorous standards for compatibility that Mesosphere requires. Percona Server for MongoDB is available to all users of DC/OS 1.10 and newer as a beta solution through the DC/OS Service Catalog, with full Mesosphere certification coming soon.

Quotes

William Freiberg, COO of Mesosphere
"Mesosphere offers the most scalable platform for data services and distributed computing, spanning multi-cloud and on-premise environments. We've seen an increase in the number of customers asking for greater support for MongoDB. Integration of Percona Server for MongoDB within the DC/OS provides our mutual customers with enterprise-grade database features and functionality on the industry-leading platform for modern applications."  

Peter Zaitsev,  Co-founder and CEO of Percona
"As enterprises look to deploy and migrate their open source databases to the cloud, Percona is expanding and evolving our offerings to ensure database administrators working in this environment have all the tools and support they need to optimize performance and support their organizations. We are committed to continuing to invest in new partnerships to help our customers take advantage of the flexibility, scalability and economics of cloud and container environments."

Company Information

Press Contact
Brigit Valencia
For Percona
(360) 597-4516
bdbvalencia@gmail.com 

About Percona

With more than 3,000 customers worldwide, Percona is the only company that delivers enterprise-class solutions for MySQL®, MariaDB®, MongoDB®, and PostgreSQL across traditional and cloud-based platforms. The company provides SoftwareSupportConsulting, and Managed Services to large, well-known global brands such as Cisco Systems, Time Warner Cable, Alcatel-Lucent, Rent the Runway and the BBC, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. Well established as thought leaders, Percona experts author content for the Percona Database Performance Blog and the Percona Live Open Source Database Conferences draw attendees and expert technical speakers from around the world. For more information, visit www.percona.com.

Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Percona via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum